[1] Zhang H, Jia N, Zhang YT, et al.Analysis of effects of drug-drug interactions on safety and efficacy of atorvastatin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 43-46. [2] Sharma M, Poh Loh K, Nightingale G, et al.Polypharmacy and potentially lnappropriate medication use in geriatric oncology[J]. J Geriatr Oncol, 2016, 7(5): 346-353. [3] Yin LX,Zhang LH.Guidance book on drug use for special groups: Guidance on drug use for the elderly(特殊人群用药指导丛书: 老年人用药指导)[M]. Beijing: People's Medical Publishing House,2012: 87-89. [4] January CT, Wann LS, Calkins H, et al.2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons[J]. Circulation, 2019, 140(2): e125-e151. [5] Schwandt A, Denkinger M, Fasching P, et al.Comparison of MDRD, CKD-EPI, and cockcroft-gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes[J]. J Diabetes Complications, 2017, 31(9): 1376-1383. [6] Christensen K, Doblhammer G, Rau R, et al.Ageing populations: the challenges ahead[J]. Lancet, 2009, 374(9696): 1196-1208. [7] Kaufman DW, Kelly JP, Rosenberg L, et al.Recent patterns of medication use in the ambulatory adult population of the United States: the slone survey[J]. JAMA, 2002, 287(3): 337-344. [8] Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research, Committee of Clinical Toxicology of Chinese Society of Toxicology. Expert consensus on risk management of polypharmacy in elderly[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(10): 627-640. [9] Morin L, Johnell K, Laroche ML, et al.The Epidemiology of polypharmacy in older adults: register-based prospective cohort study[J]. Clin Epidemiol, 2018, 10: 289-298. [10] Screever EM, Meijers WC, van Veldhuisen DJ, et al. New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations[J]. Expert Opin Pharmacother, 2017, 18(7): 645-655. [11] Johnell K, Klarin I.The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish prescribed drug register[J]. Drug Saf, 2007, 30(10): 911-918. [12] Turgeon J, Michaud V, Steffen L.The dangers of polypharmacy in elderly patients[J]. JAMA Intern Med, 2017, 177(10): 1544. [13] Rosas-Carrasco O, García-Peña C, Sánchez-García S, et al.The relationship between potential drug-drug interactions and mortality rate of elderly hospitalized patients[J]. Rev Invest Clin, 2011, 63(6): 564-573. [14] Al-Musawe L, Paula Martins A, Filipe Raposo J, et al.The association between polypharmacy and adverse health consequences in elderly type 2 diabetes mellitus patients; a systematic review and meta-analysis[J]. Diabetes Res Clin Pract, 2019, 107804: 1-7. [15] Schwinger RHG.Cardiovascular medication in elderly patients[J]. Dtsch Med Wochenschr, 2018, 143(4): 236-243. [16] Eikelboom JW, Connolly SJ, Bosch J, et al.Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med, 2017, 377(14): 1319-1330. [17] 2019 American Geriatrics Society Beers Criteria@Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria@for potentially inappropriate medication use in older adults[J]. J Am Geriatr Soc, 2019, 67(4):674-694. |